辛伐他汀治疗高脂血症的药物经济学评价综述

辛伐他汀治疗高脂血症的药物经济学评价综述

付露阳,马爱霞

中国药科大学,中国药科大学

收稿日期:2017-10-24 修回日期:2017-10-24 出版日期:2017-12-25 发布日期:2017-12-25

Pharmacoeconomic Evaluation Review on Simvastatin Treatment of Hyperlipidemia

Fu Luyang and

China pharmaceutical university,

Received:2017-10-24 Revised:2017-10-24 Online:2017-12-25 Published:2017-12-25

摘要/Abstract

摘要： 目的：系统评价辛伐他汀治疗高脂血症的经济性评价。结果：通过计算机及手工检索中国知网(CNKI)、万方数据知识平台、百链、维普、Pubmed、Science Direct、Web of Science等数据库中搜寻相关辛伐他汀治疗高脂血症和其他他汀类药物的经济性研究文献。结果：最终纳入8篇文献，英文5篇，中文3篇，在高脂血症治疗中，辛伐他汀相较于其他治疗药物有更好的成本-效果。结论：与其他他汀类药物相比，辛伐他汀在高脂血疾病治疗中，有较好的治疗效果，更能提高患者的生命质量，是具有较好的成本-效果方案。

Abstract: Objective：To systematically evaluate of simvastatin economic for the treatment of hyperlipidemia. Methods： A systematic review of literatures was conducted via CNKI，Wanfang Data，Bailian Data，VIP，Pubmed，ScienceDirect，Web of Science and ect. To identify pharmacoeconomics evaluation literatures and non-economic studies related to simvastatin treatment of hyperlipidemia and other statins. Results： A total of 8 studies were included and five studies in English and 3 studies in China，in the hyperlipidemia treatment，simvastatin had a better cost-effectiveness compared with other drugs. Conclusion： Compared with other statins，simvastatin in hyperlipidemia disease treatment has good treatment effect，improving the life quality of patients. Simvastatin is a dominant or cost-effective treatment opinion.

付露阳,马爱霞. 辛伐他汀治疗高脂血症的药物经济学评价综述[J]. .

Fu Luyang and. Pharmacoeconomic Evaluation Review on Simvastatin Treatment of Hyperlipidemia[J]. .

参考文献

[1] 董亚琳, 董卫华. 3种治疗高脂血症药物的经济学分析[J]. 中国药房, 2001(10):23-24.
[2] 孙汶雯. 引入Markov模型对调脂药进行药物经济学评价研究[D]. 北京中医药大学, 2012.
[3] 孙汶雯. 引入Markov模型对调脂药进行药物经济学评价研究[D]. 北京中医药大学, 2012.
[4] GANDHI S K, JENSEN M M, FOX K M, et al. Cost-effectiveness of rosuvastatin in comparison with generic atorvastatin and simvastatin in a Swedish population at high risk of cardiovascular events[J]. Clinicoecon Outcomes Res, 2012,4:1-11.
[5] KANG H Y, KO S K, LIEW D. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions[J]. Clin Ther, 2009,31(12):2919-2930, 2916-2918.
[6] JOHANNESSON M, JONSSON B, KJEKSHUS J, et al. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group[J]. N Engl J Med, 1997,336(5):332-336.
[7] ARAUJO D V, RIBEIRO D S C, BAHIA L R, et al. [Analysis of cost-effectiveness of simvastatin versus atorvastatin in the secondary prevention of cardiovascular events within the Brazilian public healthcare system][J]. Value Health, 2011,14(5 Suppl 1):S29-S32.
[8] 黎小妍, 徐乐加, 张平, 等. 阿托伐他汀和辛伐他汀调脂疗效的成本-效果分析[J]. 今日药学, 2012(03):167-169.
[9] 黄海平. 高血脂症3种治疗方案的经济学评价[J]. 卫生经济研究, 2012(04):54-55.
[10] 柏蓉. 3种不同他汀类药物治疗高脂血症的成本-效果分析[J]. 中国药房, 2015(26):3620-3622.
[11] LACHAINE J, MERIKLE E, TARRIDE J E, et al. A model for assessing the cost-effectiveness of atorvastatin and simvastatin in achieving Canadian low-density lipoprotein cholesterol targets[J]. Clin Ther, 2007,29(3):519-528.
[12] ARAUJO D V, RIBEIRO D S C, BAHIA L R, et al. [Analysis of cost-effectiveness of simvastatin versus atorvastatin in the secondary prevention of cardiovascular events within the Brazilian public healthcare system][J]. Value Health, 2011,14(5 Suppl 1):S29-S32.
[13] COSTA-SCHARPLATZ M, RAMANATHAN K, FRIAL T, et al. Cost-effectiveness analysis of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health system perspective[J]. Clin Ther, 2008,30(7):1345-1357.
[14] 郭姣, 朴胜华, 石忠峰, 等. 高脂血症中医证候分布规律文献研究[J]. 广州中医药大学学报, 2013(05):609-614.
[15] GANDHI S K, JENSEN M M, FOX K M, et al. Cost-effectiveness of rosuvastatin in comparison with generic atorvastatin and simvastatin in a Swedish population at high risk of cardiovascular events[J]. Clinicoecon Outcomes Res, 2012,4:1-11.